A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Asthma

Interventions

DRUG: povorcitinib
OTHER: placebo
DRUG: ICS-LABA

Sponsor

Incyte Corporation